Literature DB >> 15934067

Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor.

Jeffrey N Siegel1, Bo-Guang Zhen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15934067     DOI： 10.1002/art.21243

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  8 in total

Review 1.  [Measuring disease activity for rheumatoid arthritis].

Authors:  D Aletaha; T Stamm; J Smolen
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

2.  Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

Authors:  Paul P Tak; William Rigby; Andrea Rubbert-Roth; Charles Peterfy; Ronald F van Vollenhoven; William Stohl; Emma Healy; Eva Hessey; Mark Reynard; Tim Shaw
Journal:  Ann Rheum Dis       Date:  2011-10-19       Impact factor: 19.103

3.  Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.

Authors:  Yoshiya Tanaka; Masayoshi Harigai; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Kazuhiko Yamamoto; Nobuyuki Miyasaka; Takao Koike; Minoru Kanazawa; Takuya Oba; Toru Yoshinari; Daniel Baker
Journal:  Ann Rheum Dis       Date:  2011-11-25       Impact factor: 19.103

4.  Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol.

Authors:  B D Lacroix; M O Karlsson; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-10-29

5.  Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

Authors:  Jacques Tebib; Xavier Mariette; Pierre Bourgeois; René-Marc Flipo; Philippe Gaudin; Xavier Le Loët; Paul Gineste; Laurent Guy; Colin D Mansfield; Alain Moussy; Patrice Dubreuil; Olivier Hermine; Jean Sibilia
Journal:  Arthritis Res Ther       Date:  2009-06-23       Impact factor: 5.156

6.  Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Authors:  E C Keystone; M C Genovese; L Klareskog; E C Hsia; S T Hall; P C Miranda; J Pazdur; S-C Bae; W Palmer; J Zrubek; M Wiekowski; S Visvanathan; Z Wu; M U Rahman
Journal:  Ann Rheum Dis       Date:  2008-12-09       Impact factor: 19.103

7.  Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds.

Authors:  Vibeke Strand; Mark Kosinski; Ari Gnanasakthy; Usha Mallya; Shephard Mpofu
Journal:  Health Qual Life Outcomes       Date:  2014-03-05       Impact factor: 3.186

8.  Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary method.

Authors:  James M S Wason; Martin Jenkins
Journal:  Rheumatology (Oxford)       Date:  2016-06-23       Impact factor: 7.580
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.